查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球分子細胞遺傳學市場：按產品和服務（套件、試劑、探針、儀器、軟體、服務）、按技術（FISH、CISH、比較雜合反應）、按最終用戶、按應用（癌症、遺傳學、性病）-預測至 2028 年
市場調查報告書
商品編碼
1419286

全球分子細胞遺傳學市場：按產品和服務（套件、試劑、探針、儀器、軟體、服務）、按技術（FISH、CISH、比較雜合反應）、按最終用戶、按應用（癌症、遺傳學、性病）-預測至 2028 年

Molecular Cytogenetics Market by Product (Kits, Reagents, Probes, Instrument, Software, Services), Technique (FISH, CISH, Comparative Genomic Hybridization (Array-based, Standard)), Application (Cancer, Genetics Disorders) - Global Forecast to 2028
出版日期: | 出版商: MarketsandMarkets | 英文 235 Pages | 訂單完成後即時交付

價格
簡介目錄
調查範圍
調查年份 2021-2028
基準年 2022年
預測期 2023-2028
考慮單位 金額（十億美元）
部分 按產品/服務、技術、應用程式、最終用戶、地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東/非洲

2023年分子細胞遺傳學市場規模為31億美元，預計2028年將達49億美元，預測期間內複合年成長率為9.9%。

癌症、遺傳疾病等慢性病的盛行率不斷上升，導致疾病早期診斷和疾病核心病因診斷的普及不斷提高。這些患者的管理需要緊急、及時的治療。研究和診斷程序的整體增加​​導致更多地採用分子細胞遺傳學來確保疾病的準確診斷。這正在推動整體市場的成長。

分子細胞遺傳學市場的套件和試劑部分經歷了顯著成長，主要是由於癌症等疾病發病率的增加以及對個人化醫療關注所推動。

由於分子細胞遺傳學在臨床病理學和研究中的滲透不斷增加，分子細胞遺傳學市場中的比較雜合反應領域正在顯著成長。

目前，癌症領域在分子細胞遺傳學市場中呈現最高的成長率。由於人口老化和基因變化導致癌症發生率不斷上升，是推動這一領域成長的主要因素。

2022年，臨床和研究實驗室領域的成長率最高。這是由於對用於疾病診斷的先進細胞遺傳學產品的需求不斷增加。

預計亞太地區在預測期內的複合年成長率最高。預計該地區的成長將主要集中在中國和日本。老年人口增加、癌症發病率上升、醫療保健支出增加、人均收入增加、對先進技術的需求增加、亞太國家私營醫療保健部門的擴大、新興市場的迅速發展這些努力正在推動該地區的市場開拓。

該報告研究了全球分子細胞遺傳學市場，包括按產品/服務、技術、應用、最終用戶、地區和進入市場的公司概況分類的趨勢。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 介紹
  • 市場動態
  • 價格分析
  • 專利分析
  • 貿易分析
  • 價值鏈分析
  • 供應鏈分析
  • 生態系分析
  • 波特五力分析
  • PESTLE分析
  • 監管分析
  • 2022-2023年主要會議和活動
  • 影響客戶業務的趨勢/干擾
  • 主要相關人員和採購標準
  • 案例研究分析

第6章分子細胞遺傳學市場，依產品與服務

  • 介紹
  • 套件/試劑
  • 裝置
  • 消耗品
  • 軟體、服務

第7章分子細胞遺傳學市場（依技術）

  • 介紹
  • 比較雜合反應
  • 螢光原位雜合反應
  • 顯色原位雜合反應
  • 其他

第8章分子細胞遺傳學市場，依應用

  • 介紹
  • 遺傳疾病
  • 癌症
  • 個人化醫療
  • 其他

第9章分子細胞遺傳學市場，依最終用戶分類

  • 介紹
  • 臨床及研究機構
  • 學術研究所
  • 製藥和生物技術公司
  • 其他

第 10 章分子細胞遺傳學市場（按地區）

  • 介紹
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第11章競爭形勢

  • 概述
  • 主要參與企業的策略
  • 主要市場參與企業的收益佔有率分析
  • 市場佔有率分析
  • 企業評價矩陣
  • Start-Ups/小型企業評估矩陣
  • 競爭格局及趨勢

第12章 公司簡介

  • 主要參與企業
    • F. HOFFMANN-LA ROCHE LTD.
    • DANAHER CORPORATION
    • AGILENT TECHNOLOGIES, INC.
    • ABBOTT LABORATORIES
    • THERMO FISHER SCIENTIFIC, INC.
    • ILLUMINA INC.
    • REVVITY
    • PACIFIC BIOSCIENCES
    • BIO-RAD LABORATORIES, INC.
    • BIO-TECHNE CORPORATION
    • GENEDX
    • ONCOCYTE CORPORATION
    • BIOVIEW
  • 其他公司
    • OXFORD GENE TECHNOLOGY IP LIMITED（PART OF SYSMEX）
    • APPLIED SPECTRAL IMAGING, INC.
    • CYTOTEST INC.
    • KROMATID, INC.
    • GENIAL GENETIC SOLUTIONS LTD.
    • CYTOGNOMIX, INC.
    • METASYSTEMS
    • SCIGENE
    • BIOMODAL
    • BIOCARE MEDICAL
    • BIODOT
    • ONCODNA

第13章附錄

簡介目錄
Product Code: BT 4883

Report Description

Scope of the Report
Years Considered for the Study2021-2028
Base Year2022
Forecast Period2023-2028
Units ConsideredValue (USD) Billion
SegmentsProduct, technique, application, end user, and region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa

The molecular cytogenetics market is valued at an estimated USD 3.1 billion in 2023 and is projected to reach USD 4.9 billion by 2028, at a CAGR of 9.9% during the forecast period. Increasing in the incidence of chronic diseases like cancer and genetic diseases has lead to the increase in prevalence of the diagnosis of the diseases at earlier stage and diagnosis of the core cause of disease. Urgent and timely treatment is required to manage these patients. The overall increase in the number of research and diagnostic procedures is leading to the increased adoption of molecular cytogenetics in order to ensure theaccurate diagnosis of the diseases. This is driving the overall growth of the market.

"Kits & Reagents segment accounted for the highest growth rate in the molecular cytogenetics market, by product, during the forecast period."

The molecular cytogenetics market is bifurcated into kits & reagents, instruments, consumables and software & services on the basis of product. The kits & reagents segment in the molecular cytogenetics market is experiencing substantial growth, largely driven by the increasing incidence of diseases such as cancers and increasing focus on personalized medicines.

"Comparative genomic hybridization segment accounted for the highest growth rate in the molecular cytogenetics market, by technique, during the forecast period."

The molecular cytogenetics market is bifurcated into comparative genomic hybridization, fluorescence in-situ hybridization, chromogenic in-situ hybridization and other techniques on the basis of technique. The comparative genomic hybridization segment in the molecular cytogenetics market is experiencing substantial growth, largely driven by the increasing penetration of molecular cytogenetics in clinical pathology and research.

"Cancer segment accounted for the highest growth rate in the molecular cytogenetics market, by applications, during the forecast period."

The global molecular cytogenetics market is bifurcated into genetic disorders, cancer, personalized medicine and other applications. The cancer segment is currently witnessing the highest growth rate within the molecular cytogenetics market. The rising geriatric population and rising incidence of cancer due to genetic changes are the major factors driving this segment's growth.

"Clinical & research laboratories segment accounted for the highest CAGR"

Based on end users, the molecular cytogenetics market is segmented into clinical & research laboratories, academic research institutes, pharmaceutical & biotechnology companies and other end users. In 2022, the clinical & research laboratories segment accounted for the highest growth rate. This can be attributed to the increased demand for advanced cytogenetics products for disease diagnosis.

"Asia Pacific: The fastest-growing region molecular cytogenetics market"

The global molecular cytogenetics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Anticipated growth in this region will primarily focus on China and Japan. Factors such as a growing elderly population, rising cancer prevalence, increased healthcare expenditures, higher per capita income, escalating demand for advanced technology, the expansion of private healthcare sectors across several APAC nations, and the existence of rapidly developing markets are steering the market's growth in this region.

The break-up of the profile of primary participants in the molecular cytogenetics market:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are Thermo Fisher Scientific Inc. (US), Illumina Inc. (US), Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), Abbott Laboratories (US), Agilent Technologies, Inc. (US), Pacific Biosciences (US), Bio-Rad Laboratories, Inc. (US), Bio-Techne Corporation (US), GeneDx (US), Oncocyte Corporation (US), BioView (Israel), Oxford Gene Technology IP, Limited. (UK), Applied Spectral Imaging, Inc. (US), Cyto-Test Inc. (US), KromaTiD, Inc. (US), Genial Genetic Solutions, Ltd. (UK), Cytognomix, Inc. (Canada), MetaSystems (Germany), SciGene (US), Biomodal (UK), Biocare Medical (US), BioDot (US), OncoDNA (Belgium).

Research Coverage:

This research report categorizes the molecular cytogenetics market by product (kits & reagents, instruments, consumables and software & services), technique (comparative genomic hybridization, fluorescence in-situ hybridization, chromogenic in-situ hybridization and other techniques), application (genetic disorders, cancer, personalized medicine and other applications), end user (clinical & research laboratories, academic research institutes, pharmaceutical & biotechnology companies and other end users), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities and challenges, influencing the growth of the molecular cytogenetics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions and services, key strategies, acquisitions, and agreements. New product launches and recent developments associated with the molecular cytogenetics market. Competitive analysis of upcoming startups in the molecular cytogenetics market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall molecular cytogenetics market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (increasing incidence of cancer and genetic disorders, growing focus on targeted cancer treatment, rapid growth in aging population and subsequent increase in prevalence of chronic diseases, increasing penetration of molecular cytogenetics in clinical pathological testing), restraints (high cost of advanced instruments, unfavorable reimbursement scenario), opportunities (untapped emerging markets in Asia) and challenges (transition from FISH to array-based techniques) influencing the growth of the molecular cytogenetics market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular cytogenetics market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the molecular cytogenetics market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular cytogenetics market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Agilent Technologies, Inc. (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), among others in the molecular cytogenetics market strategies.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION
    • 1.3.2 GEOGRAPHIC SCOPE
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 1 MOLECULAR CYTOGENETICS MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.3.1.3 Growth forecast
      • 2.3.1.4 CAGR projections
    • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 6 MOLECULAR CYTOGENETICS MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE ANALYSIS
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 RISK ASSESSMENT
  • 2.8 GROWTH RATE ASSUMPTIONS
  • 2.9 RECESSION IMPACT

3 EXECUTIVE SUMMARY

    • FIGURE 8 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 9 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023 VS. 2028 (USD MILLION)
    • FIGURE 10 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)
    • FIGURE 11 MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    • FIGURE 12 MOLECULAR CYTOGENETICS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 MOLECULAR CYTOGENETICS MARKET OVERVIEW
    • FIGURE 13 RISING PREVALENCE OF CANCER AND GENETIC DISORDERS TO DRIVE MARKET
  • 4.2 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028
    • FIGURE 14 KITS & REAGENTS TO CONTINUE TO DOMINATE MARKET IN 2028
  • 4.3 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2023 VS. 2028
    • FIGURE 15 COMPARATIVE GENOMIC HYBRIDIZATION TO CONTINUE TO DOMINATE MOLECULAR CYTOGENETICS MARKET IN 2028
  • 4.4 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2023 VS. 2028
    • FIGURE 16 CANCER WILL CONTINUE TO DOMINATE MOLECULAR CYTOGENETICS MARKET IN 2028
  • 4.5 MOLECULAR CYTOGENETICS MARKET, BY END USER, 2023 VS. 2028
    • FIGURE 17 CLINICAL & RESEARCH LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.6 MOLECULAR CYTOGENETICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN MOLECULAR CYTOGENETICS MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 19 MOLECULAR CYTOGENETICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 MARKET DRIVERS
      • 5.2.1.1 Increasing incidence of cancer and genetic disorders
    • TABLE 1 PREVALENCE OF GENETIC DISORDERS (2021)
    • TABLE 2 ESTIMATED NUMBER OF NEW CANCER CASES GLOBALLY, BY TYPE OF CANCER, 2020 VS. 2025
    • TABLE 3 GLOBAL CANCER INCIDENCE, BY REGION, 2020 VS. 2025
      • 5.2.1.2 Growing focus on targeted cancer treatment
      • 5.2.1.3 Increasing aging population and subsequent rise in prevalence of chronic diseases
      • 5.2.1.4 Increasing penetration of molecular cytogenetics in clinical pathological testing
    • 5.2.2 MARKET RESTRAINTS
      • 5.2.2.1 High cost of advanced instruments
      • 5.2.2.2 Unfavorable reimbursement scenario
    • 5.2.3 MARKET OPPORTUNITIES
      • 5.2.3.1 Untapped emerging markets
    • 5.2.4 MARKET CHALLENGES
      • 5.2.4.1 Transition from FISH to array-based techniques
  • 5.3 PRICING ANALYSIS
    • 5.3.1 PRICING MODEL ANALYSIS
    • TABLE 4 INDICATIVE PRICING ANALYSIS FOR MOLECULAR CYTOGENETIC PRODUCTS
    • 5.3.2 AVERAGE SELLING PRICE OF MOLECULAR CYTOGENETIC PRODUCTS, BY KEY PLAYER
    • TABLE 5 AVERAGE SELLING PRICE OF MOLECULAR CYTOGENETIC PRODUCTS
  • 5.4 PATENT ANALYSIS
    • 5.4.1 PATENT ANALYSIS OF MOLECULAR CYTOGENETIC PRODUCTS (JANUARY 2013-DECEMBER 2022)
    • 5.4.2 MOLECULAR CYTOGENETICS MARKET: LIST OF MAJOR PATENTS
  • 5.5 TRADE ANALYSIS
    • 5.5.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
      • 5.5.1.1 Import data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
      • 5.5.1.2 Export data for diagnostic and laboratory reagents, by country, 2018-2022 (USD million)
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 20 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • 5.7 SUPPLY CHAIN ANALYSIS
    • FIGURE 21 MOLECULAR CYTOGENETICS MARKET: SUPPLY CHAIN ANALYSIS
  • 5.8 ECOSYSTEM ANALYSIS
    • FIGURE 22 MOLECULAR CYTOGENETICS MARKET: ECOSYSTEM ANALYSIS
    • 5.8.1 ROLE IN ECOSYSTEM
    • TABLE 6 MOLECULAR CYTOGENETICS MARKET: ECOSYSTEM ROLE
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 7 MOLECULAR CYTOGENETICS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF BUYERS
    • 5.9.4 BARGAINING POWER OF SUPPLIERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 PESTLE ANALYSIS
  • 5.11 REGULATORY ANALYSIS
    • TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 11 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.11.1 NORTH AMERICA
      • 5.11.1.1 US
      • 5.11.1.2 Canada
    • 5.11.2 EUROPE
    • TABLE 12 EUROPE: CLASSIFICATION OF DEVICES
    • 5.11.3 ASIA PACIFIC
      • 5.11.3.1 China
      • 5.11.3.2 Japan
    • TABLE 13 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
      • 5.11.3.3 India
    • 5.11.4 LATIN AMERICA
      • 5.11.4.1 Brazil
      • 5.11.4.2 Mexico
    • 5.11.5 MIDDLE EAST
    • 5.11.6 AFRICA
  • 5.12 KEY CONFERENCES & EVENTS IN 2022-2023
    • TABLE 14 MOLECULAR DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
    • FIGURE 23 REVENUE SHIFT AND REVENUE POCKETS FOR MOLECULAR CYTOGENETICS MARKET
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR CYTOGENETIC PRODUCTS
    • TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MOLECULAR CYTOGENETIC PRODUCTS (%)
    • 5.14.2 BUYING CRITERIA
    • FIGURE 25 KEY BUYING CRITERIA FOR MOLECULAR CYTOGENETIC END USERS
    • TABLE 16 KEY BUYING CRITERIA
  • 5.15 CASE STUDY ANALYSIS
    • 5.15.1 CASE STUDY: CYTOGENETIC ANALYSIS OF WISKOTT-ALDRICH SYNDROME

6 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 17 MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
  • 6.2 KITS & REAGENTS
    • TABLE 18 MOLECULAR CYTOGENETICS MARKET FOR KITS & REAGENTS, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 19 MOLECULAR CYTOGENETICS MARKET FOR KITS & REAGENTS, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.1 TESTING KITS
      • 6.2.1.1 Growing advancements in test kits to support market growth
    • TABLE 20 MOLECULAR CYTOGENETICS MARKET FOR TESTING KITS, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.2 PROBES
      • 6.2.2.1 Increased usage of probes for in situ hybridization to propel market
    • TABLE 21 MOLECULAR CYTOGENETICS MARKET FOR PROBES, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.3 FLUORESCENT AFFINITY REAGENTS
      • 6.2.3.1 Development of novel cytogenetic reagents to drive growth
    • TABLE 22 MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENT AFFINITY REAGENTS, BY REGION, 2021-2028 (USD MILLION)
    • 6.2.4 OTHER KITS & REAGENTS
    • TABLE 23 MOLECULAR CYTOGENETICS MARKET FOR OTHER KITS & REAGENTS, BY REGION, 2021-2028 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 INCREASING USAGE OF INSTRUMENTS IN DRUG DISCOVERY TO DRIVE MARKET
    • TABLE 24 MOLECULAR CYTOGENETICS MARKET FOR INSTRUMENTS, BY REGION, 2021-2028 (USD MILLION)
  • 6.4 CONSUMABLES
    • 6.4.1 INCREASING AWARENESS ABOUT EARLY-STAGE CANCER DIAGNOSIS TO DRIVE MARKET
    • TABLE 25 MOLECULAR CYTOGENETICS MARKET FOR CONSUMABLES, BY REGION, 2021-2028 (USD MILLION)
  • 6.5 SOFTWARE & SERVICES
    • 6.5.1 GROWING NEED FOR SOFTWARE SOLUTIONS FOR HIGH CONTENT SCREENING TO PROPEL MARKET
    • TABLE 26 MOLECULAR CYTOGENETICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2021-2028 (USD MILLION)

7 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE

  • 7.1 INTRODUCTION
    • TABLE 27 MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
  • 7.2 COMPARATIVE GENOMIC HYBRIDIZATION
    • TABLE 28 MOLECULAR CYTOGENETICS MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY TYPE, 2021-2028 (USD MILLION)
    • TABLE 29 MOLECULAR CYTOGENETICS MARKET FOR COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.1 ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION
      • 7.2.1.1 Rising prevalence of human genetic disorders to support market growth
    • TABLE 30 MOLECULAR CYTOGENETICS MARKET FOR ARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION)
    • 7.2.2 STANDARD COMPARATIVE GENOMIC HYBRIDIZATION
      • 7.2.2.1 Increased focus on cancer research to drive growth
    • TABLE 31 MOLECULAR CYTOGENETICS MARKET FOR STANDARD COMPARATIVE GENOMIC HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION)
  • 7.3 FLUORESCENCE IN SITU HYBRIDIZATION
    • 7.3.1 ADVANCES IN FLUORESCENCE MICROSCOPY TO BOOST MARKET
    • TABLE 32 MOLECULAR CYTOGENETICS MARKET FOR FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION)
  • 7.4 CHROMOGENIC IN SITU HYBRIDIZATION
    • 7.4.1 COST-EFFECTIVENESS OVER FLUORESCENT IN SITU HYBRIDIZATION FISH TO SUPPORT ADOPTION
    • TABLE 33 MOLECULAR CYTOGENETICS MARKET FOR CHROMOGENIC IN SITU HYBRIDIZATION, BY REGION, 2021-2028 (USD MILLION)
  • 7.5 OTHER TECHNIQUES
    • TABLE 34 MOLECULAR CYTOGENETICS MARKET FOR OTHER TECHNIQUES, BY REGION, 2021-2028 (USD MILLION)

8 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 35 MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
  • 8.2 GENETIC DISORDERS
    • 8.2.1 INCREASING EFFORTS TO STUDY GENETIC ACTIVITIES TO SUPPORT MARKET GROWTH
    • TABLE 36 MOLECULAR CYTOGENETICS MARKET FOR GENETIC DISORDERS, BY REGION, 2021-2028 (USD MILLION)
  • 8.3 CANCER
    • 8.3.1 STRATEGIC DEVELOPMENTS IN CANCER RESEARCH TO DRIVE MARKET GROWTH
    • TABLE 37 MOLECULAR CYTOGENETICS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION)
  • 8.4 PERSONALIZED MEDICINE
    • 8.4.1 INITIATIVES BY MARKET PLAYERS FOR PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH
    • TABLE 38 MOLECULAR CYTOGENETICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021-2028 (USD MILLION)
  • 8.5 OTHER APPLICATIONS
    • TABLE 39 MOLECULAR CYTOGENETICS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021-2028 (USD MILLION)

9 MOLECULAR CYTOGENETICS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 40 MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 9.2 CLINICAL & RESEARCH LABORATORIES
    • 9.2.1 GROWING RESEARCH INTENSITY TO DRIVE USAGE OF MOLECULAR CYTOGENETIC PRODUCTS
    • TABLE 41 MOLECULAR CYTOGENETICS MARKET FOR CLINICAL & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
  • 9.3 ACADEMIC RESEARCH INSTITUTES
    • 9.3.1 INCREASE IN RESEARCH FUNDING FOR LIFE SCIENCE PROJECTS TO DRIVE MARKET
    • TABLE 42 MOLECULAR CYTOGENETICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION)
  • 9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.4.1 GROWING IMPORTANCE OF MOLECULAR CYTOGENETICS FOR DRUG DISCOVERY TO SUPPORT MARKET GROWTH
    • TABLE 43 MOLECULAR CYTOGENETICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION)
  • 9.5 OTHER END USERS
    • TABLE 44 MOLECULAR CYTOGENETICS MARKET FOR OTHER END USERS, BY REGION, 2021-2028 (USD MILLION)

10 MOLECULAR CYTOGENETICS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 45 MOLECULAR CYTOGENETICS MARKET, BY REGION, 2021-2028 (USD MILLION)
  • 10.2 NORTH AMERICA
    • TABLE 46 LIST OF RELATED CONFERENCES HELD IN NORTH AMERICA
    • FIGURE 26 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET SNAPSHOT
    • TABLE 47 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 48 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 49 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 50 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 51 NORTH AMERICA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.1 NORTH AMERICA: RECESSION IMPACT
    • 10.2.2 US
      • 10.2.2.1 US to dominate North American molecular cytogenetics market
    • TABLE 52 US: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 53 US: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 54 US: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 55 US: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.2.3 CANADA
      • 10.2.3.1 Rising prevalence of cancer to drive market
    • TABLE 56 CANADA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 57 CANADA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 58 CANADA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 59 CANADA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.3 EUROPE
    • FIGURE 27 EUROPE: CANCER INCIDENCE & MORTALITY, 2012-2035
    • TABLE 60 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 61 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 62 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 63 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 64 EUROPE: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.1 EUROPE: RECESSION IMPACT
    • 10.3.2 GERMANY
      • 10.3.2.1 Increasing healthcare expenditure with favorable government policies to propel market
    • TABLE 65 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 66 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 67 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 68 GERMANY: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.3 UK
      • 10.3.3.1 Availability of government funding and strategic collaborations to boost market
    • TABLE 69 UK: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 70 UK: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 71 UK: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 72 UK: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Increasing government investments to boost growth of French molecular cytogenetics market
    • TABLE 73 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 74 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 75 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 76 FRANCE: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Favorable funding scenario to drive adoption of molecular cytogenetics
    • TABLE 77 ITALY: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 78 ITALY: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 79 ITALY: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 80 ITALY: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Growing demand for genetic testing to create major growth opportunities for market players
    • TABLE 81 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 82 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 83 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 84 SPAIN: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 85 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 86 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 87 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 88 REST OF EUROPE: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 28 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET SNAPSHOT
    • TABLE 89 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
    • TABLE 90 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 91 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 92 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 93 ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.1 ASIA PACIFIC: RECESSION IMPACT
    • 10.4.2 CHINA
      • 10.4.2.1 Increased cancer cases to propel market
    • TABLE 94 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 95 CHINA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 96 CHINA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 97 CHINA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 98 CHINA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.3 JAPAN
      • 10.4.3.1 Universal health reimbursement policy to support market growth
    • TABLE 99 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 100 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 101 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 102 JAPAN: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.4 INDIA
      • 10.4.4.1 Increasing adoption of technology to support market growth
    • TABLE 103 INDIA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 104 INDIA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 105 INDIA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 106 INDIA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • TABLE 107 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 108 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 109 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 110 REST OF ASIA PACIFIC: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 EXPANSIONS OF KEY PLAYERS IN LATIN AMERICAN REGION TO BOOST MARKET
    • TABLE 111 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 112 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 113 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 114 LATIN AMERICA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.5.2 LATIN AMERICA: RECESSION IMPACT
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 ADVANCEMENTS IN DIAGNOSTIC TECHNOLOGIES AND INCREASED HEALTHCARE INVESTMENT TO PROPEL MARKET
    • TABLE 115 MIDDLE EAST & AFRICA: MOLECULAR CYTOGENETICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)
    • TABLE 116 MIDDLE EAST & AFRICA: MOLECULAR CYTOGENETICS MARKET, BY TECHNIQUE, 2021-2028 (USD MILLION)
    • TABLE 117 MIDDLE EAST & AFRICA: MOLECULAR CYTOGENETICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)
    • TABLE 118 MIDDLE EAST & AFRICA: MOLECULAR CYTOGENETICS MARKET, BY END USER, 2021-2028 (USD MILLION)
    • 10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 STRATEGIES OF KEY PLAYERS
    • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MOLECULAR CYTOGENETICS MARKET
    • TABLE 119 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MOLECULAR CYTOGENETICS MANUFACTURING COMPANIES
  • 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 29 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN MOLECULAR CYTOGENETICS MARKET
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 30 MOLECULAR CYTOGENETICS MARKET SHARE, BY KEY PLAYER, 2022
    • TABLE 120 MOLECULAR CYTOGENETICS MARKET: DEGREE OF COMPETITION
  • 11.5 COMPANY EVALUATION MATRIX
    • 11.5.1 LIST OF EVALUATED VENDORS
    • 11.5.2 STARS
    • 11.5.3 EMERGING LEADERS
    • 11.5.4 PERVASIVE PLAYERS
    • 11.5.5 PARTICIPANTS
    • FIGURE 31 MOLECULAR CYTOGENETICS MARKET: COMPANY EVALUATION MATRIX, 2022
    • 11.5.6 COMPANY FOOTPRINT ANALYSIS
    • TABLE 121 COMPANY TYPE FOOTPRINT
    • TABLE 122 COMPANY REGIONAL FOOTPRINT
  • 11.6 STARTUP/SME EVALUATION MATRIX
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • FIGURE 32 MOLECULAR CYTOGENETICS MARKET: STARTUP/SME EVALUATION MATRIX, 2022
    • 11.6.5 COMPETITIVE BENCHMARKING
    • FIGURE 33 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF TOP PLAYERS IN MOLECULAR CYTOGENETICS MARKET
    • TABLE 123 MOLECULAR CYTOGENETICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
  • 11.7 COMPETITIVE SCENARIO & TRENDS
    • 11.7.1 PRODUCT LAUNCHES
    • TABLE 124 KEY PRODUCT LAUNCHES & APPROVALS (JANUARY 2020-NOVEMBER 2023)
    • 11.7.2 DEALS
    • TABLE 125 KEY DEALS (JANUARY 2020-NOVEMBER 2023)
    • 11.7.3 OTHER DEVELOPMENTS
    • TABLE 126 OTHER DEVELOPMENTS (JANUARY 2020-NOVEMBER 2023)

12 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, MnM View Right to win, Strategic choices made, Weaknesses and competitive threats) **
  • 12.1 KEY PLAYERS
    • 12.1.1 F. HOFFMANN-LA ROCHE LTD.
    • TABLE 127 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
    • FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022)
    • 12.1.2 DANAHER CORPORATION
    • TABLE 128 DANAHER CORPORATION: COMPANY OVERVIEW
    • FIGURE 35 DANAHER CORPORATION: COMPANY SNAPSHOT (2022)
    • 12.1.3 AGILENT TECHNOLOGIES, INC.
    • TABLE 129 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
    • FIGURE 36 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.4 ABBOTT LABORATORIES
    • TABLE 130 ABBOTT LABORATORIES: COMPANY OVERVIEW
    • FIGURE 37 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2022)
    • 12.1.5 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 131 THERMO FISHER SCIENTIFIC, INC.: COMPANY OVERVIEW
    • FIGURE 38 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.6 ILLUMINA INC.
    • TABLE 132 ILLUMINA INC.: COMPANY OVERVIEW
    • FIGURE 39 ILLUMINA INC.: COMPANY SNAPSHOT (2022)
    • 12.1.7 REVVITY
    • TABLE 133 REVVITY: COMPANY OVERVIEW
    • FIGURE 40 REVVITY: COMPANY SNAPSHOT (2022)
    • 12.1.8 PACIFIC BIOSCIENCES
    • TABLE 134 PACIFIC BIOSCIENCES: COMPANY OVERVIEW
    • FIGURE 41 PACIFIC BIOSCIENCES: COMPANY SNAPSHOT (2022)
    • 12.1.9 BIO-RAD LABORATORIES, INC.
    • TABLE 135 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
    • FIGURE 42 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022)
    • 12.1.10 BIO-TECHNE CORPORATION
    • TABLE 136 BIO-TECHNE CORPORATION: COMPANY OVERVIEW
    • FIGURE 43 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2022)
    • 12.1.11 GENEDX
    • TABLE 137 GENEDX: COMPANY OVERVIEW
    • FIGURE 44 GENEDX: COMPANY SNAPSHOT (2022)
    • 12.1.12 ONCOCYTE CORPORATION
    • TABLE 138 ONCOCYTE CORPORATION: COMPANY OVERVIEW
    • FIGURE 45 ONCOCYTE CORPORATION: COMPANY SNAPSHOT (2022)
    • 12.1.13 BIOVIEW
    • TABLE 139 BIOVIEW: COMPANY OVERVIEW
  • 12.2 OTHER PLAYERS
    • 12.2.1 OXFORD GENE TECHNOLOGY IP LIMITED (PART OF SYSMEX)
    • 12.2.2 APPLIED SPECTRAL IMAGING, INC.
    • 12.2.3 CYTOTEST INC.
    • 12.2.4 KROMATID, INC.
    • 12.2.5 GENIAL GENETIC SOLUTIONS LTD.
    • 12.2.6 CYTOGNOMIX, INC.
    • 12.2.7 METASYSTEMS
    • 12.2.8 SCIGENE
    • 12.2.9 BIOMODAL
    • 12.2.10 BIOCARE MEDICAL
    • 12.2.11 BIODOT
    • 12.2.12 ONCODNA
  • *Details on Business Overview, Products Offered, Recent Developments, MnM View, Right to win, Strategic choices made, Weaknesses and competitive threats might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS